Gene therapy using CRISPR technology for Facioscapulohumeral muscular dystrophy (FSHD)
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)
This study is exploring a new way to treat Facioscapulohumeral muscular dystrophy (FSHD) by using special techniques to quiet down a harmful gene, which could lead to a promising treatment for this condition that currently has no cure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10898604 on NIH RePORTER |
What this research studies
This research focuses on developing a new gene therapy approach to treat Facioscapulohumeral muscular dystrophy (FSHD), a common muscular dystrophy caused by the harmful expression of the DUX4 gene. The researchers aim to inhibit this toxic gene expression using innovative RNA silencing and editing techniques that do not alter the DNA, thus minimizing risks. The study will involve testing these methods in animal models to evaluate their effectiveness in reducing DUX4 levels in skeletal muscles. If successful, this could lead to a groundbreaking treatment for a currently untreatable condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Facioscapulohumeral muscular dystrophy (FSHD).
Not a fit: Patients with other forms of muscular dystrophy or those without a diagnosis of FSHD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from FSHD, potentially improving their muscle function and quality of life.
How similar studies have performed: While the specific RNA editing approaches being tested are novel, similar gene therapy techniques have shown promise in other genetic disorders, indicating potential for success.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Harper, Scott Q — Research Inst Nationwide Children's Hosp
- Study coordinator: Harper, Scott Q
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.